# Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

> **NCT03808922** · PHASE3 · RECRUITING · sponsor: **Ansun Biopharma, Inc.** · enrollment: 274 (estimated)

## Conditions studied

- Lower Respiratory Tract Infection
- Parainfluenza
- Immunocompromised
- COVID-19

## Interventions

- **DRUG:** DAS181
- **DRUG:** Placebo
- **DRUG:** DAS181 COVID-19
- **DRUG:** DAS181 OL

## Key facts

- **NCT ID:** NCT03808922
- **Lead sponsor:** Ansun Biopharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-05-23
- **Primary completion:** 2028-09-01
- **Final completion:** 2028-09-01
- **Target enrollment:** 274 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03808922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03808922, "Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03808922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*